Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report. Key Metrics Metric Q4 2023 Q4 2024 Change vs. Expectations Revenue $2.52 billion $2.91 billion 16% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback